STING1 and neoplasm: To address this challenge, we develop LipoNCs@pGSDMB, a tumor-selective nanoplatform that harnesses the elevated reactive oxygen species (ROS) levels in bone metastases to spatiotemporally release a polymeric STING agonist (PSA) and gasdermin B plasmid (pGSDMB) (Fig. 1).